Ieq Capital LLC boosted its holdings in shares of CME Group Inc. (NASDAQ:CME – Get Rating) by 77.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,743 shares of the financial services provider’s stock after buying an additional 2,942 shares during the period. Ieq Capital LLC’s holdings in CME Group were worth $1,194,000 as of its most recent SEC filing.
Several other institutional investors have also recently bought and sold shares of CME. RB Capital Management LLC raised its holdings in CME Group by 11.4% during the first quarter. RB Capital Management LLC now owns 1,419 shares of the financial services provider’s stock worth $338,000 after buying an additional 145 shares during the last quarter. Prudential PLC acquired a new position in CME Group during the first quarter worth $1,709,000. Cetera Investment Advisers raised its holdings in CME Group by 5.8% during the first quarter. Cetera Investment Advisers now owns 3,485 shares of the financial services provider’s stock worth $829,000 after buying an additional 190 shares during the last quarter. Sequoia Financial Advisors LLC acquired a new position in CME Group during the first quarter worth $281,000. Finally, Candriam Luxembourg S.C.A. raised its holdings in shares of CME Group by 9.5% in the first quarter. Candriam Luxembourg S.C.A. now owns 25,230 shares of the financial services provider’s stock valued at $6,001,000 after purchasing an additional 2,181 shares during the last quarter. Institutional investors and hedge funds own 85.09% of the company’s stock.
CME Group Price Performance
Shares of NASDAQ:CME opened at $173.13 on Wednesday. The company has a quick ratio of 1.02, a current ratio of 1.02 and a debt-to-equity ratio of 0.12. The firm has a market capitalization of $62.28 billion, a PE ratio of 23.56, a P/E/G ratio of 3.53 and a beta of 0.40. CME Group Inc. has a twelve month low of $166.54 and a twelve month high of $256.94. The company has a 50-day moving average price of $174.21 and a two-hundred day moving average price of $183.57.
CME Group Increases Dividend
The firm also recently announced a None dividend, which was paid on Wednesday, January 18th. Shareholders of record on Wednesday, December 28th were given a dividend of $4.50 per share. The ex-dividend date of this dividend was Tuesday, December 27th. This is a positive change from CME Group’s previous None dividend of $3.25. CME Group’s dividend payout ratio (DPR) is currently 54.42%.
Insiders Place Their Bets
In other news, Director William R. Shepard acquired 48,645 shares of the business’s stock in a transaction dated Friday, November 4th. The stock was bought at an average cost of $170.00 per share, for a total transaction of $8,269,650.00. Following the completion of the transaction, the director now owns 247,843 shares of the company’s stock, valued at $42,133,310. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.30% of the company’s stock.
Analyst Upgrades and Downgrades
Several brokerages have recently commented on CME. UBS Group lowered their target price on shares of CME Group from $226.00 to $220.00 in a report on Thursday, January 5th. Citigroup lowered their target price on shares of CME Group from $214.29 to $210.00 in a report on Thursday, January 12th. Rosenblatt Securities lowered their target price on shares of CME Group from $171.00 to $161.00 and set a “sell” rating for the company in a report on Wednesday, October 5th. Deutsche Bank Aktiengesellschaft lowered their target price on shares of CME Group from $207.00 to $200.00 in a report on Wednesday, January 11th. Finally, Morgan Stanley lowered their target price on shares of CME Group from $208.00 to $196.00 and set an “equal weight” rating for the company in a report on Wednesday, January 11th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, CME Group currently has a consensus rating of “Hold” and an average target price of $220.73.
CME Group Profile
CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income products.
- Get a free copy of the StockNews.com research report on CME Group (CME)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- When Will Crane Holdings Take Flight?
Receive News & Ratings for CME Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group and related companies with MarketBeat.com's FREE daily email newsletter.